NEXLIZET

Peak

bempedoic acid and ezetimibe

NDAORALTABLET

Approved

Feb 2020

Lifecycle

Peak

Competitive Pressure

0/100

Mechanism of Action

Adenosine Triphosphate-Citrate Lyase Inhibitors

Pharmacologic Class:

Adenosine Triphosphate-Citrate Lyase Inhibitor

Loss of Exclusivity

LOE Date

Jun 19, 2040

173 months away

Patent Expiry

Jun 19, 2040

Exclusivity Expiry

Mar 22, 2027

Patent Records (5)

Patent #	Expiry	Type	Use Code
7335799	Dec 3, 2030	Substance	—
11744816	Mar 14, 2036		U-3692
10912751	Mar 14, 2036		U-3224
11760714	Jun 19, 2040	Product	—
11926584	Jun 19, 2040		U-3873

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers